Gastroenterology
Clinical
In acute lower GI bleeding, there may be no benefit to early colonoscopy
Does early colonoscopy within 24 hours of presentation for adults with acute lower gastrointestinal bleeding improve outcomes, compared with...
News
Microbiome therapeutic offers durable protection against C. difficile recurrence
“The hope would be that one or more ... would probably replace the vast majority of FMT [procedures] that we do clinically,”said Dr. Sahil Khanna...
News
Fecal microbiota transplantation impacts microRNAs implicated in recurrent C. difficile
“The findings from this study are extremely exciting and promising for the creation of novel therapeutics for patients with C. difficile...
Clinical
FMT cuts risk of bloodstream infections in patients with recurrent CDI
In patients with recurrent Clostridioides difficile infections (CDI), does fecal microbiota transplantation (FMT) decrease the risk of...
Clinical
Emergent ERCP in acute cholangitis linked with better outcomes
Are outcomes better for patients with acute cholangitis (AC) if endoscopic retrograde cholangiopancreatography (ERCP) is done emergently (within...
News
COVID-19 may alter gut microbiota
Changes in gut microorganisms may contribute to severe disease and long-term symptoms after the virus clears.
Clinical
Anticoagulation and antiplatelet therapy after GI bleed cut mortality, ischemic events
In patients who present with a gastrointestinal bleed (GIB) while on an anticoagulants (AC) or antiplatelets (AP), what are the risks and benefits...
News
Updated USPSTF HBV screening recommendation may be a ‘lost opportunity’
The recommendation defines risk groups more narrowly than the CDC, AASLD, and some research suggests risk-based screening is ineffective for...
News
Anorexia and diarrhea top list of GI symptoms in COVID-19 patients
Increased ALT levels were the most common sign of abnormal liver function in adults with severe COVID-19.
News
COVID-19 vaccines: Safe for immunocompromised patients?
Data are limited thus far, and the safety and efficacy of the COVID-19 vaccines in immunocompromised patients remain unknown.